F-star Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow-5.32
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
F-star Therapeutics's peg ratio stands at -5.32. That is below the Healthcare sector average of 12.15. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
F-star Therapeutics sits lower the Healthcare benchmark (12.15) with a PEG ratio of -5.32. That is roughly 143.8% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether -5.32 is attractive depends on F-star Therapeutics's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how F-star Therapeutics's PEG ratio evolved across reporting periods, while the comparison chart places FSTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, PEG ratio is commonly used to spot outliers. F-star Therapeutics's reading of -5.32 (sector avg 12.15) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
